PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663439
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1663439
Digital Breast Tomosynthesis Market size was valued at US$ 2,814.5 Million in 2024, expanding at a CAGR of 14.20% from 2025 to 2032.
Digital breast tomosynthesis, sometimes referred to as 3D mammography, is a very successful technique for identifying breast cancer, especially in dense breast tissue. Unlike normal mammography, which uses 2D images, digital breast tomosynthesis uses a succession of 2D photos to build a 3D image. Using an X-ray tube, digital breast tomosynthesis (DBT) creates several 2D images of the breast from various perspectives. This procedure is comparable to a typical mammography, except that the breast is squeezed and positioned in an arc. Following digitization, the pictures are fused to create a three-dimensional image (three-dimensional) that offers more detailed information and facilitates the differentiation of potentially malignant tissue from healthy tissue. By providing a more precise and thorough image of the breast, this technique improves the diagnostic potential of breast cancer screening. Due to increased knowledge of the advantages of digital breast tomosynthesis (DBT) equipment for breast cancer screening, such as improved diagnostic accuracy and decreased recall rates, the market for this technology is expanding quickly. Technological breakthroughs like greater 3D imaging and software improvements for higher-quality images are also driving this growth. The need for DBT equipment is also being driven by the rising incidence of breast cancer, especially in women 40 years of age and older. The efforts of healthcare institutions and the government to promote early identification of breast cancer are also fueling the market's growth.
Digital Breast Tomosynthesis Market- Market Dynamics
Rising Prevalence of Breast Cancer
One of the main factors propelling the market's expansion is the increasing incidence of breast cancer worldwide. The World Health Organization estimates that 2.3 million women received a breast cancer diagnosis in 2020, and 6,85,000 people died from the disease globally. By the end of 2020, 7.8 million women had been diagnosed with breast cancer in the past five years, making it the most frequent cancer worldwide. Through the use of a process called digital breast tomosynthesis, breast tissue can be reconstructed in three dimensions and viewed as successive parts throughout the breast. It reduces the false-positive or recall rate while increasing the identification of breast cancer. Additionally, it makes ductal carcinoma in situ (DCIS), which are tiny, aberrant tissue growths that are limited to the breast's milk ducts, easier to identify. The digital breast tomosynthesis industry is driven by the fact that these tumours rarely cause harm to the patient if removed early.
Digital Breast Tomosynthesis Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 14.20% over the forecast period (2025-2032)
Based on product segmentation, the standalone 3D systems were predicted to show maximum market share in the year 2024
Based on end use segmentation, hospitals were the leading segment in 2024
On the basis of region, North America was the leading revenue generator in 2024
The Global Digital Breast Tomosynthesis Market is segmented on the basis of Product, End Use, and Region.
On the basis of product, the market is segregated into Standalone 3D Systems and 2D/3D Combination Systems. In 2024, the market was dominated by the standalone 3D systems category ascribed to the device's easy-to-use features, enhanced lesion visualization, and technical developments that produce accurate detection results. Furthermore, digital breast tomosynthesis provides thorough imaging of the breast, which helps with early detection, particularly in cases of dense breast tissue. In order to enhance visibility and facilitate precise early detection, it makes use of three-dimensional imaging techniques. As a result, the use of DBT in healthcare facilities has stimulated market expansion. For instance, approximately 87% of U.S. mammography centres with FDA certification had at least one DBT system in place as of June 2023.
Based on end use, the market is divided into Hospitals, Clinics, Diagnostics Centers, and Others. In 2024, the hospitals category held a dominant market share. Hospitals with extensive medical facilities show a high need for cutting-edge imaging technologies, such as DBT, to improve their diagnostic capacities. Early diagnosis of breast cancer and other abnormalities is facilitated by the more precise and detailed imaging of breast tissue made possible by the introduction of DBT into clinical settings. The need for DBT equipment is further increased by the fact that hospitals frequently serve a sizable patient population. Hospitals continue to lead the adoption and implementation of DBT, making them the largest end-user sector in the DBT equipment market, even though diagnostic centres and other healthcare facilities also use this technology.
Digital Breast Tomosynthesis Market- Geographical Insights
In 2024, North America held a dominant position in the global market for Digital Breast Tomosynthesis. It can be linked to both the rising incidence of breast cancer and the existence of major industry participants in this area. In 2023, for instance, approximately 1.9 million people received a cancer diagnosis, according to the American Cancer Society. Additionally, the region's market is growing due in large part to the sophisticated healthcare infrastructure that offers early cancer diagnosis facilities as well as technical breakthroughs and research and development. The government's programs, funding, and investments aimed at raising public awareness of breast cancer are also anticipated to contribute to the market's growth over the forecast period.
However, throughout the projected period, the Europe region is anticipated to see the fastest CAGR. This is explained by the growing number of older adults in this area as well as recent developments in technology. The rising incidence of cancer, better medical facilities, and an emphasis on research and development have also influenced the market's expansion. For instance, the European Breast Cancer Coalition, or EUROPA DONNA, reports that 16% of women in the WHO Europe Region died from breast cancer in 2022. The implementation of DBT in this area has also increased as a result of initiatives and healthcare programs that have raised public awareness of early identification. In order to help breast cancer survivors and emphasize the value of early detection and timely access to high-quality care, ARENA started a breast cancer awareness collection in partnership with the Keep A Breast Foundation.
The market for digital breast tomosynthesis is extremely competitive, with a number of major competitors such as GE Healthcare, Analogic Corporation, Trivitron Healthcare, Siemens Healthineers, Hologic Inc. and others actively pursuing strategic initiatives and fighting for market dominance. To obtain a competitive edge, these businesses concentrate on developing new products, improving technology, and diversifying their product lines. In order to improve their product offerings and meet the changing demands of their clientele in terms of sustainability, performance, and efficiency, these businesses consistently invest in research and development. For instance, in July 2024, with the new 21HQ613D-B diagnostic monitor, which was just approved for sale in the United States by the Food and Drug Administration, LG Electronics (LG) is growing its business in the B2B medical device market.
Recent Development
January 2023: Blackford Analysis Ltd. was acquired by Bayer in order to solve the shortage of radiologists and the growing need for medical imaging. Basically, it's to enhance the quality of life for patients by promoting innovation in radiology through the use of AI in clinical workflow.
January 2023: The first UK proton beam therapy trial for breast cancer was started by University College London Hospitals (UCLH). This trial will allow radiotherapy beams to be aimed more precisely, primarily at patients who are at risk for lifelong cardiac problems. In addition to lowering off-target radiation to the heart, proton beam therapy will assist in concentrating on radiation doses that are appropriate for breast tissue.
August 2022: Whiterabbit introduced its ACT program, which uses digital breast tomosynthesis images, also known as 3D mammograms, to analyze them and help diagnose breast cancer automatically.
May 2022: Therapixel obtained EUR 15 million in Series B fundraising to expand its commercial presence in the US. Additionally, the financing will help expand the capabilities of its mammography reading assistance and enable the development of new features for its MammoScreen platform.